Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.